EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Risk stratification and treatment goals in pulmonary arterial hypertension

Fabio Dardi iD, Athénaïs Boucly iD, Raymond Benza iD, Robert Frantz iD, Valentina Mercurio, Horst Olschewski iD, Göran Rådegran iD, Lewis J Rubin, Marius M Hoeper iD

European Respiratory Journal · 2024-10 · 64 (4) · 2401323

DOI: 10.1183/13993003.01323-2024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Respiratory Journal, online erschienen am 29.08.2024. Verfasst von Fabio Dardi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 148-mal zitiert (Crossref) und nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Risk stratification has gained an increasing role in predicting outcomes and guiding the treatment of patients with pulmonary arterial hypertension (PAH). The most predictive prognostic factors are three noninvasive parameters (World Health Organization functional class, 6-min walk distance and natriuretic peptides) that are included in all currently validated risk stratification tools. However, suffering from limitations mainly related to reduced specificity of PAH severity, these variables may not always be adequate in isolation for guiding individualised treatment decisions. Moreover, with effective combination treatment regimens and emerging PAH therapies, markers associated with pulmonary vascular remodelling are expected to become of increasing relevance in guiding the treatment of patients with PAH. While reaching a low mortality risk, assessed with a validated risk tool, remains an important treatment goal, preliminary data suggest that invasive haemodynamics and cardiac imaging may add incremental value in guiding treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Arterial HypertensionHumansRisk AssessmentPrognosisBiomarkersHypertension, PulmonaryHemodynamicsNatriuretic PeptidesSeverity of Illness IndexWalk Test

Substanzen

BiomarkersNatriuretic Peptides

Autor:innen und Institutionen

  • Cardiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
  • Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Department of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA.
  • Department of Translational Medical Sciences, Federico II University, Naples, Italy.
  • Div. Pulmonology, Department Internal Medicine, Medical University of Graz, Graz, Austria.

ORCID-Profile: Fabio Dardi, Athénaïs Boucly, Raymond Benza, Robert Frantz, Horst Olschewski, Göran Rådegran, Marius M Hoeper

Zitieren

APA

Dardi, F., Boucly, A., Benza, R., Frantz, R., Mercurio, V., Olschewski, H., Rådegran, G., Rubin, L. J., & Hoeper, M. M. (2024). Risk stratification and treatment goals in pulmonary arterial hypertension. European Respiratory Journal, 64(4), 2401323. https://doi.org/10.1183/13993003.01323-2024

Vancouver

Dardi F, Boucly A, Benza R, Frantz R, Mercurio V, Olschewski H, et al. Risk stratification and treatment goals in pulmonary arterial hypertension. European Respiratory Journal. 2024;64(4):2401323. doi:10.1183/13993003.01323-2024

BibTeX
@article{Dardi2024,
  author = {Dardi, Fabio and Boucly, Athénaïs and Benza, Raymond and Frantz, Robert and Mercurio, Valentina and Olschewski, Horst and Rådegran, Göran and Rubin, Lewis J and Hoeper, Marius M},
  title = {Risk stratification and treatment goals in pulmonary arterial hypertension},
  journal = {European Respiratory Journal},
  year = {2024},
  volume = {64},
  number = {4},
  pages = {2401323},
  doi = {10.1183/13993003.01323-2024}
}
Kostenlos starten →